Chad Mao
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Background Genetic diagnosis has become increasingly important to guide clinical decision making for patients with dilated cardiomyopathy (DCM). Disease-causing (P/LP) missense variants in the gene RBM20 cause a highly penetrant arrhythmogenic dilated cardiomyopathy (DCM), but the role of truncating RBM20 variants ( RBM20tvs ) is unclear. Objective Assess the contribution of RBM20tvs to DCM. Methods We assembled an international cohort of DCM patients with RBM20 variants and used data from the genome-first UK Biobank (UKB) to assess the etiologic fraction, natural history and penetrance of RBM20tvs . Results The etiologic fraction of RBM20tvs in arrhythmogenic DCM was modest (0.53[0.32,0.67], p=7.5×10 -5 ). RBM20tv DCM patients presented to referral centers later in life than RBM20 P/LP DCM patients (53±10 vs. 34±18 years, p=4×10 -3 ), and were less likely to have a family history of sudden cardiac arrest (20% vs. 65%, p= 0.046) or cardiomyopathy (20% vs. 78% p=5.4×10 -3 ). There was no significant difference in age- and sex-adjusted incident major heart failure or arrhythmia events between RBM20tv and RBM20 P/LP DCM patients, though sex-adjusted lifetime hazard was reduced in RBM20tv DCM (HR 0.15[0.03,0.66],p=0.009). In UKB, lifetime incidence of cardiomyopathy, heart failure, or major ventricular arrhythmia diagnosis was lower in participants with RBM20tvs than in those with TTNtvs (HR 0.55 [0.36,0.84], p=5.9×10 -3 ). Conclusions RBM20tvs contribute to arrhythmogenic DCM phenotypes, but confer milder disease severity alone than RBM20 P/LP variants, and reduced lifetime disease penetrance compared to TTNtvs . Their potential for additive interactions with other damaging variants should be considered in DCM patients and families.
Year:
2025
Background Fontan circulatory failure (FCF) is a chronic state in palliated single ventricle heart disease with high morbidity and mortality including heart failure, multisystem end-organ disease, and need for heart transplant. Specific FCF morbidities have not been rigorously defined, limiting study of how FCF morbidities impact pre- and post-HT outcomes. We hypothesized that FCF-related morbidities affect survival from heart transplant waitlisting through 1-year post-heart transplant. Methods This 20-center, retrospective cohort study collected demographic, medical/surgical history, waitlist data, and peri- and post-heart transplant data, and a priori defined FCF-specific morbidities in Fontan patients who were listed for heart transplant from 2008-2022. Univariate 2-group statistics compared surviving individuals with those who 1) died anytime from waitlisting to 1-year post-heart transplant, 2) died on the waitlist, 3) underwent transplant and died within 1-year post-transplant. Using covariates from both univariate analyses, multivariable logistic regression determined the primary study outcome of independent FCF risk factors for mortality between waitlist and 1-year post-heart transplant Results Of 409 waitlisted patients, 24 (5.9%) died on the waitlist. Of the 341 (83.4%) who underwent HT, 27 (8.5%) did not survive to 1-year. Univariate risk factors for waitlist death included higher aortopulmonary collateral burden, > 1 hospitalization in prior year, younger age, sleep apnea, higher NYHA class, non-enrollment in school or work, and single-parent home. Risk factors for 1-year post-heart transplant mortality included hypoplastic left heart syndrome diagnosis, patent fenestration, anatomic Fontan obstruction, clinical cyanosis (pulse oximetry 1 hospitalization in the year prior to waitlisting (adjusted odds ratio 2.0, p=0.05) and clinical cyanosis (adjusted odds ratio 5.0, p=0.002). Conclusions Patients with Fontan palliation selected for heart transplant have significant mortality from waitlisting through transplant. Among FCF specific morbidities, cyanosis is associated with worsened survival and necessitates further study. Clinical morbidity of any type requiring repeated hospital admission also should prompt consideration of heart transplant. Clinical Perspective What is new? Survival through heart transplant in patients with Fontan physiology selected for waitlisting has increased from previous reports, but this patient group still has significant risk of mortality. Risk factors for waitlist mortality and post-transplant mortality are different. Cyanosis and repeated hospitalizations prior to listing are independent risk factors for mortality between waitlisting and 1-year post-heart transplant. What are the clinical implications? To successfully manage a patient through the entire transplant process, attention to mitigating different risks in the waitlist and post-transplant phase is necessary. Repeated hospitalization or significant cyanosis in a patient with Fontan physiology should prompt consideration of heart transplant.
Year:
2024
BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD). METHODS: Children with HF attributable to LVSD were randomized to sacubitril/valsartan versus enalapril to assess the efficacy and safety of sacubitril/valsartan at 52 weeks of follow-up. The primary end point of the study was to determine whether sacubitril/valsartan was superior to enalapril for the treatment of pediatric patients with HF attributable to systemic LVSD, assessed using a primary global rank end point consisting of ranking patients from worst to best on the basis of clinical events such as death, listing for urgent heart transplant, mechanical life support requirement, worsening HF, New York Heart Association (NYHA)/Ross class, Patient Global Impression of Severity (PGIS), and Pediatric Quality of Life Inventory physical functioning domain. The change from baseline to 52 weeks in NT-proBNP (N-terminal pro–B-type natriuretic peptide) was an exploratory end point. RESULTS: A total of 375 children (mean age, 8.1±5.6 years; 52% female) were randomized to sacubitril/valsartan (N=187) or enalapril (N=188). At week 52, no significant difference was observed between the 2 treatment arms in the global rank end point (Mann-Whitney probability, 0.52 [95% CI, 0.47–0.58]; Mann-Whitney odds, 0.91 [95% CI, 0.72–1.14]; P =0.42). At week 52, clinically meaningful reductions were observed in both treatment arms in NYHA/Ross, PGIS, Patient Global Impression of Change, and NT-proBNP, without significant differences between groups. Adverse events were similar between treatment arms (incidence: sacubitril/valsartan, 88.8%; enalapril, 87.8%), and the safety profile of sacubitril/valsartan was acceptable in children. CONCLUSIONS: In this study, sacubitril/valsartan did not show superiority over enalapril in the treatment of children with HF attributable to systemic LVSD using the prespecified global rank end point. However, both treatment arms showed clinically meaningful improvements over 52 weeks. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02678312.
Year:
2024
Background Children awaiting heart transplant (Tx) have a high risk of death due to donor organ scarcity. Historically, ventricular assist devices (VADs) reduced waitlist mortality, prompting increased VAD use. We sought to determine whether the VAD survival benefit persists in the current era. Methods Using the Scientific Registry of Transplant Recipients, we identified patients listed for Tx between 3/22/2016 and 9/1/2020. We compared characteristics of VAD and non‐VAD groups at Tx listing. Cox proportional hazards models were used to identify risk factors for 1‐year waitlist mortality. Results Among 5054 patients, 764 (15%) had a VAD at Tx listing. The VAD group was older with more mechanical ventilation and renal impairment. Unadjusted waitlist mortality was similar between groups; the curves crossed ~90 days after listing ( p = .55). In multivariable analysis, infant age (HR 2.77, 95%CI 2.13–3.60), Black race (HR 1.57, 95%CI 1.31–1.88), congenital heart disease (HR 1.23, 95%CI 1.04–1.46), renal impairment (HR 2.67, 95%CI 2.19–3.26), inotropes (HR 1.28, 95%CI 1.09–1.52), and mechanical ventilation (HR 2.23, 95%CI 1.84–2.70) were associated with 1‐year waitlist mortality. VADs were not associated with mortality in the first 90 waitlist days but were protective for those waiting ≥90 days (HR 0.43, 95%CI 0.26–0.71). Conclusions In the current era, VADs reduce waitlist mortality, but only for those waitlisted ≥90 days. The differential effect by race, size, and VAD type is less clear. These findings suggest that Tx listing without VAD may be reasonable if a short waitlist time is anticipated, but VADs may benefit those expected to wait >90 days.
Year:
2024
Background Cardiac fitness training in pediatric heart transplant recipients can improve functional capacity. Widespread implementation has been limited mostly due to logistical constraints, specifically related to travel. The aim of this study was to implement and assess a virtual cardiac fitness program for pediatric heart transplant patients. Methods Participants were between the age of 10 and 20 years old. All subjects completed an initial 6MWT, strength/flexibility assessment, and QOL assessment with the PROMIS measurement. Participants then underwent a 16‐week intervention with exercise sessions twice weekly for 30 min with a trained exercise physiologist over a virtual platform. At the end of the intervention period, participants repeated a 6MWT, strength/flexibility assessment, and PROMIS measurement. Throughout the study, patients wore a FitBit accelerometer to monitor daily activity levels. Results Thirteen individuals were enrolled. Mean age was 15.4 years (SD =3.4) with a mean post‐transplant period of 9.7 years (SD = 4.3). Session attendance was 83%. Post‐intervention measurements showed improvements in 6MWT (median, +21 m, p = .02), push‐up repetitions (median, +5 rep, p = .0005), wall‐sit duration (median, +10 s, p = .001), plank duration (median, +9 s, p = .03), sit‐up repetitions (median, +7 rep, p = .002), and sit and reach distance (median, +5 cm, p = .04). PROMIS measurement showed significant improvements in self‐reported fatigue (Δz‐score, −7.7, p = .008) and sleep impairment (Δ z ‐score, −5.9, p = .002). Average daily step count increased 1464 steps per day per patient ( p = .008). Conclusion We have demonstrated the successful implementation of a virtual cardiac fitness with excellent adherence and improvement in physical fitness and QOL metrics.
Year:
2022
Collaborators (35)
Sharlene Day
Associate Professor
University of Pennsylvania
Anjali T. Owens
Assistant Professor, Clinician-Educator
University of Pennsylvania Perelman School of Medicine
Ching Kit Chen
-
Jacek Kusa
Medical University of Silesia
Eric Smith
University of Michigan
Benjamin Meder
W3 Professor
University Hospital Heidelberg
Bruna Filipa Gomes Botelho Quintas
Fachärztin
University Hospital Heidelberg
Daniel Judge
Professor
Medical University of South Carolina
Julia Cadrin-Tourigny
Clinical Assistant Professor
Université de Montréal
Adam Helms
Assistant Professor
University of Michigan
Charles E. Canter
-
Melissa Cousino
University of Michigan
Vasanth Vedantham
Professor
University of California, San Francisco
Joan Sanchez-de-Toledo
Director del Área del Corazón
University of Pittsburgh
Damien Bonnet
-
Jinyoung Song
professor
Samsung Medical Center
Hyoung-Doo Lee
Prof
Pusan National University
Andrew D Krahn
Professor
The University of British Columbia
Diane Fatkin
Victor Chang Cardiac Research Institute
Gianfranco Sinagra
University of Trieste
Arene Butto
Assistant Professor of Pediatrics, Emory University School of Medicine; Cardiac Intensive Care; Advanced Cardiac Therapies
Children's Healthcare of Atlanta
David Rosenthal
Stanford University
Cynthia James
Associate Professor
Johns Hopkins University
Nosheen Reza
University of Pennsylvania
Euan A. Ashley
Professor
Stanford University School of Medicine
Joseph Rossano
Children's Hospital of Philadelphia
Ardan M. Saguner
-
Maria Bano
Assistant Professor
University of Texas Southwestern Medical School
Kristen Medo
Research Services Professional
University of Colorado Anschutz Medical Campus
Luisa Mestroni
Professor of Medicine
University of Colorado Anschutz Medical Campus
Andreas S. Barth
Assistant Professor
Johns Hopkins University
Jennifer Conway
-
Perry Elliott
University College London
Brian Feingold
University of Pittsburgh
Matthew Bock
Associate Professor
University of California, San Diego
Make your next move.
Prepare your application
Review drafts before you send them.